LydiaRx
The people

Leadership and independent oversight.

What delivers programmes are people. Our team below have built the UK's largest health-research programmes, The 100,000 Genomes Project and Our Future Health, led European RWD programmes The Get Real Institute, run one of the world's largest academic–industry sequencing partnerships and US$1 billion pharmaceutical software & data programmes, and taken two biotechnology companies to acquisition by GSK and Novartis.

EXPLORE THIS PAGE Leadership and advisers
Leadership and advisers

Hover over or tap a photo to read more.

Dr Andrew RoddamDr Andrew RoddamChair, Governance and Ethics Board (independent)

Former Chief Executive of Our Future Health, the UK's largest health-research programme, built from a new organisation into a national cohort designed for five million participants. Oxford DPhil statistician; Chair of SNOMED International. Holds every LydiaRx programme to its published standard, independently of the company.

Najib RehmanNajib RehmanCo-Founder and Chief Executive

Twenty years in life-sciences data and AI. At Pfizer, took over a US$1 billion global enterprise-analytics programme in difficulty and led its recovery and delivery over ten years, directing some 300 people across three continents. Adviser to Pfizer and AstraZeneca on large-scale data analysis. Leads delivery in-country.

Prof. Kathleen BarnesProf. Kathleen BarnesScientific Committee Chair

Director of the Colorado Center for Personalized Medicine and Professor of Medicine, University of Colorado Anschutz. Led the Center's partnership with Regeneron to sequence 450,000 patients; principal investigator on studies collecting more than 165,000 biospecimens in under-represented populations. Owns cohort and analysis design.

Khurem FarooqKhurem FarooqStrategic Adviser

Three-time biotechnology chief executive. Led Aiolos Bio to acquisition by GSK and Gyroscope Therapeutics to acquisition by Novartis, some US$2.9 billion in aggregate exit value. Former senior vice president at Genentech/Roche. Advises on what pharmaceutical partners expect of sovereign data.

Dr Mark BaleDr Mark BaleAdviser, National Programme Design and Bioethics

Programme Director of the UK's 100,000 Genomes Project; former Deputy Chief Scientific Adviser, Department of Health and Social Care; Head of Science Partnerships at Genomics England, 2015–22. Chaired the Council of Europe's bioethics committee and led G7 work on pathogen surveillance.

DF
Daud FarooqCo-Founder and Legal Director

Two decades as a lawyer and law-firm managing partner in the United Kingdom, structuring government and sovereign-fund transactions across Pakistan, Türkiye, the Middle East and North Africa. Architect of the data-sovereignty model, the supplier terms and the Sovereignty and Trust Charter; owns ethics and consent.

Dr Shahid HanifDr Shahid HanifHealth Data and Pharma Commercial Adviser

Managing Director of the GetReal Institute; formerly Head of Health Data and Outcomes at the ABPI, where for a decade he represented the UK pharmaceutical industry on health data. Advises on the consent and data standards research partners require.

Dr Jacqueline HallDr Jacqueline HallAdviser, Clinical Research and Genomics Programme Delivery

Founder of Vivactiv, a genomics and clinical-research consultancy; some two decades in genomics, translational clinical research and advanced analytics, with leadership roles at IQVIA and the EORTC. PhD, Glasgow; postdoctoral research at McGill. Advises on clinical-research quality standards.

James PeachJames PeachAdviser, Genomics Programmes and Drug Discovery

Co-Founder and Chief Executive of Human Centric Drug Discovery, an Oxford University spin-out. Part of the team that established Genomics England and the 100,000 Genomes Project, and built its cancer genomics programme with AstraZeneca, Pfizer and Cancer Research UK. Advises on turning a cohort into research that attracts partners.

Dr Imran KausarDr Imran KausarRegulatory and Therapeutic Adviser

United Kingdom pharmaceutical physician; former roles at Sobi, Novartis Gene Therapies and Akcea; has taken rare-disease and gene-therapy products through European regulators. Advises on the clinical-governance obligations of returning findings to participants.

Beyond those named. LydiaRx draws on further senior figures from Genomics England and the Global Alliance for Genomics and Health. Each adviser participates in a personal capacity; affiliations are for identification only, as at October 2026.

Talk to the people who built it.

A briefing is with a founder.